Immutep Receives $4.6m R&D Tax Incentive
Immutep (ASX:IMM) has received a €2.59m (A$4.57m) research and development tax incentive from the French Government under its Crédit d’Impôt Recherche (CIR) scheme.
The payment recognises eligible expenditure by the company’s French subsidiary, Immutep S.A.S., on research and development conducted in the European Union during the 2024 calendar year.
The CIR, or “Research Tax Credit,” reimburses French companies for 30% of qualifying R&D expenses undertaken in Europe.
Immutep also benefits from cash rebates under the Australian Federal Government’s R&D tax incentive program for work carried out domestically.
The funds will support the ongoing and planned global clinical development of the company’s two lead immunotherapy candidates — eftilagimod alfa and IMP761.
Author's summary: Immutep received $4.6m tax incentive.
More News
- Father and three children killed in head-on collision with stolen car driven by career criminal out on parole
- Mercedes driven in zigzag manner, dragged victims: What FIR in Delhi car crash reveals
- Radiohead postpones two Copenhagen shows due to illness
- Walter Arlaud – photographie artistique en édition limitée
- Radiohead Delay European Comeback Concerts After Thom Yorke Falls Ill
- Radiohead postpone shows due to Thom Yorke's throat infection
- Nigeria’s Economy Expands by 3.98% in Q3, Boosted by Non-Oil Sector
- UK Snooker Championship 2025 LIVE: Zhao Xintong vs Long Zehuang - scores, stream & results
- Derichebourg Shares Climb 3.71% as Upward Market Momentum Strengthens
- UK Championship Snooker: Allen Trails as Zhao Xintong Advances to Last 16